Gene therapy developer Sarepta Therapeutics (NASDAQ:SRPT) lost ~25% in the premarket on Tuesday as the company disclosed the death of a patient treated with Elevidys, its FDA-approved treatment for ...
Zealand Pharma has concluded enrolment for its global, randomised Phase IIb ZUPREME-1 trial, assessing petrelintide.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback